straZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England, research site, a company spokesperson has confirmed to Fierce Biotech. The pharma's pullback is the latest in a string of industry retreats from the country that have been reported this week. Source: Fierce Biotech 12/9/2025